[China-made paclitaxel in the treatment of advanced ovarian cancer: a clinical analysis of 32 cases].
To study the effect and toxicities of China-made paclitaxel in the treatment of advanced epithelial ovarian carcinoma. Thirty-two patients were divided into two groups. single paclitaxel group (SPG): paclitaxel was only given to twelve untreated patients or those who had been given only one course of chemotherapy at a dose of 175 mg/m2 in 5% glucose 500 ml, i.v. for 3 hours; and combined paclitaxel group (CPG): paclitaxel 135 mg/m2 in 5% glucose 55 ml, i.v. for 3 hours on day 1 plus cisplatin 70-80 mg/m2 or carboplatin 300 mg/m2, i.v. on day 2, was administered to 20 patients with persistent or recurrent tumor after platinum based chemotherapy. Four weeks were defined as one course in both groups. At least two courses were given except those with tumor progression after one course. The overall response rate was 39%. It was 27% and 45% in the SPG and CPG. The chief side effects were moderate myelosuppression, peripheral neuropathy (myalgia, arthralgia, peripheral neuritis), severe alopecia, etc., but no hypersensitivity. One patient died from intestinal perforation. China-made paclitaxel is effective as in treating ovarian carcinoma especially for platinum-resistant patients. The toxic effects are tolerable to the patients.